LENZ Financial Statements From 2010 to 2024

LENZ Stock   35.50  1.18  3.44%   
LENZ Therapeutics financial statements provide useful quarterly and yearly information to potential LENZ Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on LENZ Therapeutics financial statements helps investors assess LENZ Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting LENZ Therapeutics' valuation are summarized below:
Market Capitalization
600.5 M
Earnings Share
(2.74)
We have found ninety-five available fundamental ratios for LENZ Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of LENZ Therapeutics last-minute market performance against the performance between 2010 and 2024 to make sure the company can sustain itself for few more years.

LENZ Therapeutics Total Revenue

18.11 Million

Check LENZ Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LENZ Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.6 M, Interest Expense of 48 K or Other Operating Expenses of 55.6 M, as well as many indicators such as Price To Sales Ratio of 6.57, Dividend Yield of 0.0 or PTB Ratio of 0.58. LENZ financial statements analysis is a perfect complement when working with LENZ Therapeutics Valuation or Volatility modules.
  
Check out the analysis of LENZ Therapeutics Correlation against competitors.
For more information on how to buy LENZ Stock please use our How to Invest in LENZ Therapeutics guide.

LENZ Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets205.7 M188.5 M76 M
Slightly volatile
Short and Long Term Debt Total343.9 K362 K2.7 M
Pretty Stable
Other Current LiabilitiesM4.3 M4.1 M
Slightly volatile
Total Current Liabilities4.6 M4.8 M5.9 M
Slightly volatile
Cash138.7 M185.9 M51.3 M
Slightly volatile
Cash And Short Term Investments187.2 M185.9 M69.2 M
Slightly volatile
Common Stock Shares Outstanding6.5 M8.1 M8.1 M
Slightly volatile
Liabilities And Stockholders Equity205.7 M188.5 M76 M
Slightly volatile
Total Liabilities4.6 M4.9 M6.8 M
Slightly volatile
Total Current Assets190.6 M188 M70.5 M
Slightly volatile
Short Term Debt270.8 K285 K1.5 M
Slightly volatile
Property Plant And Equipment Net304.9 K321 K4.2 M
Slightly volatile
Accounts Payable237.5 K250 K675.9 K
Very volatile
Non Current Assets Total413.2 K435 K5.6 M
Slightly volatile
Other Assets0.80.90.98
Slightly volatile
Non Current Liabilities Total73.1 K77 K2.8 M
Slightly volatile
Other Current Assets2.9 M2.2 M1.7 M
Slightly volatile
Property Plant And Equipment Gross168.3 K334.6 K64.9 K
Slightly volatile
Capital Stock6.5 M6.8 MM
Slightly volatile
Net Working Capital29.8 M42.7 M21 M
Slightly volatile
Common Stock800900980
Slightly volatile
Short Term Investments176.4 M198.4 M216.1 M
Slightly volatile
Non Current Liabilities Other52.8 K59.4 K64.7 K
Slightly volatile

LENZ Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.6 M2.4 M1.1 M
Slightly volatile
Interest Expense48 K36 K66.9 K
Slightly volatile
Other Operating Expenses55.6 M73.1 M20.6 M
Slightly volatile
Total Operating Expenses53 M70.7 M19.6 M
Slightly volatile
Research Development38.8 M29.7 M18.1 M
Slightly volatile
Cost Of Revenue3.2 M2.4 M1.1 M
Slightly volatile
Selling General Administrative3.8 MM2.9 M
Slightly volatile
Reconciled Depreciation5.5 K9.2 K3.1 K
Slightly volatile

LENZ Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow45.3 M47.7 M32.7 M
Slightly volatile
Other Non Cash Items38.9 M71.5 M14.4 M
Slightly volatile
End Period Cash Flow138.7 M185.9 M51.3 M
Slightly volatile
Depreciation3.2 M2.4 M1.1 M
Slightly volatile
Total Cash From Financing Activities180.5 K190 K50 M
Pretty Stable
Stock Based Compensation504.4 K829.1 K293.8 K
Slightly volatile
Issuance Of Capital Stock29.1 M34.7 M24.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.577.398.0461
Slightly volatile
Stock Based Compensation To Revenue0.03850.04330.0471
Slightly volatile
Capex To Depreciation7.124.510210.713
Slightly volatile
EV To Sales4.334.875.3058
Slightly volatile
Payables Turnover10.119.6281.8092
Slightly volatile
Research And Ddevelopement To Revenue3.443.874.2106
Slightly volatile
Capex To Revenue0.350.40.431
Slightly volatile
Cash Per Share16.7822.8198.1133
Slightly volatile
Days Payables Outstanding36.0137.91031.4 K
Slightly volatile
Income Quality0.420.72210.3087
Slightly volatile
Current Ratio41.1639.19558.906
Slightly volatile
Graham Number48.4788.097223.5963
Slightly volatile
Capex Per Share1.41.33280.421
Slightly volatile
Revenue Per Share1.531.721.875
Slightly volatile
Interest Debt Per Share0.03820.04020.1938
Slightly volatile
Debt To Assets0.00170.0017245
Slightly volatile
Days Of Payables Outstanding36.0137.91031.4 K
Slightly volatile
Ebt Per Ebit2.781.7053.2842
Slightly volatile
Quick Ratio41.1639.19558.906
Slightly volatile
Cash Ratio40.6838.74537.6516
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.231.12061.1655
Slightly volatile
Fixed Asset Turnover0.420.480.5208
Slightly volatile
Debt Ratio0.00170.0017245
Slightly volatile
Price Sales Ratio6.577.398.0461
Slightly volatile
Asset Turnover0.03730.04190.0457
Slightly volatile
Gross Profit Margin0.350.40.4345
Slightly volatile

LENZ Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap95.9 M101 M411.4 M
Slightly volatile

LENZ Fundamental Market Drivers

Cash And Short Term Investments185.9 M

About LENZ Therapeutics Financial Statements

LENZ Therapeutics investors use historical fundamental indicators, such as LENZ Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LENZ Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue2.4 M3.2 M
Total Revenue17.2 M18.1 M
Stock Based Compensation To Revenue 0.04  0.04 
Research And Ddevelopement To Revenue 3.87  3.44 
Capex To Revenue 0.40  0.35 
Revenue Per Share 1.72  1.53 
Ebit Per Revenue(6.34)(6.66)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for LENZ Stock Analysis

When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.